Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
94.64
+4.68 (5.20%)
At close: May 12, 2025, 4:00 PM
94.64
0.00 (0.00%)
After-hours: May 12, 2025, 7:00 PM EDT
Glaukos Revenue
Glaukos had revenue of $106.66M in the quarter ending March 31, 2025, with 24.58% growth. This brings the company's revenue in the last twelve months to $404.52M, up 23.92% year-over-year. In the year 2024, Glaukos had annual revenue of $383.48M with 21.85% growth.
Revenue (ttm)
$404.52M
Revenue Growth
+23.92%
P/S Ratio
12.12
Revenue / Employee
$406,556
Employees
995
Market Cap
5.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GKOS News
- 11 days ago - Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Glaukos Announces First Quarter 2025 Financial Results - Business Wire
- 13 days ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 19 days ago - Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - Business Wire
- 26 days ago - Glaukos Announces the Release of its 2024 Sustainability Report - Business Wire
- 4 weeks ago - Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 - Business Wire
- 2 months ago - RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution - Business Wire
- 2 months ago - FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Benzinga